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Abstract
Background: Defects in APC and regulatory cells are associated with diabetes development in NOD mice. We have shown
previously that NOD APC are not effective at stimulating CD4
+CD25
+ regulatory cell function in vitro. We hypothesize that
failure of NOD APC to properly activate CD4
+CD25
+ regulatory cells in vivo could compromise their ability to control
pathogenic cells, and activation of NOD APC could restore this defect, thereby preventing disease.
Methodology/Principal Findings: To test these hypotheses, we used the well-documented ability of complete Freund’s
adjuvant (CFA), an APC activator, to prevent disease in NOD mice. Phenotype and function of CD4
+CD25
+ regulatory cells
from untreated and CFA-treated NOD mice were determined by FACS, and in vitro and in vivo assays. APC from these mice
were also evaluated for their ability to activate regulatory cells in vitro. We have found that sick NOD CD4
+CD25
+ cells
expressed Foxp3 at the same percentages, but decreased levels per cell, compared to young NOD or non-NOD controls.
Treatment with CFA increased Foxp3 expression in NOD cells, and also increased the percentages of CD4
+CD25
+Foxp3
+ cells
infiltrating the pancreas compared to untreated NOD mice. Moreover, CD4
+CD25
+ cells from pancreatic LN of CFA-treated,
but not untreated, NOD mice transferred protection from diabetes. Finally, APC isolated from CFA-treated mice increased
Foxp3 and granzyme B expression as well as regulatory function by NOD CD4
+CD25
+ cells in vitro compared to APC from
untreated NOD mice.
Conclusions/Significance: These data suggest that regulatory T cell function and ability to control pathogenic cells can be
enhanced in NOD mice by activating NOD APC.
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Introduction
Dysregulation of the immune response in NOD mice plays a
major role in the induction of type 1 diabetes [1,2]. NOD mice are
defective in both central [3] and peripheral tolerance [1]. In
addition, antigen-presenting cells (APC) in NOD mice exhibit
various defects, including differentiation, antigen presentation and
co-stimulatory molecule expression [4–7].
It is now well established that CD4
+CD25
+ regulatory T cells,
which account for 5–10% of CD4
+ cells in healthy mice and
humans, control the development of many autoimmune diseases.
Their mechanisms of action are still controversial [8], however,
these cells absolutely require activation [9,10], presumably by
APC, to function in vitro and probably in vivo. The transcription
factor, Foxp3 appears to be critical for CD4
+CD25
+ regulatory T
cell development and function. Foxp3-deficient mice do not
develop functional CD4
+CD25
+ regulatory T cells, and ectopic
expression of Foxp3 in naive T cells converts them into cells with
regulatory function [11–13]. Studies using transgenic mice
expressing GFP under control of the Foxp3 promoter has
confirmed the relationship between Foxp3 and regulatory cell
function [8,14]. Interestingly, a recent study has found a
correlation between levels of Foxp3 expression and regulatory
function [15], suggesting that failure to maintain optimal Foxp3
expression could compromise regulatory cell function and lead to
autoimmune disease development.
Although controversial, the percentage of CD4
+CD25
+ regula-
tory T cells has been shown in some studies to be reduced in NOD
mice [16–18] and patients with type 1 diabetes [19]. On the other
hand, there is very clear evidence that this regulatory population is
functionally defective in mice and patients with type 1 diabetes
[20–22]. We have shown previously that it is not the NOD
CD4
+CD25
+ regulatory cells themselves that are defective in
assays for regulatory function, but the NOD APC that are
defective in their ability to stimulate CD4
+CD25
+ regulatory
function [16]. We speculated that this may also be the case in vivo,
and that stimulation of NOD APC in vivo could enhance their
ability to activate regulatory T cells and thusly, prevent disease.
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3739The ability of complete Freund’s adjuvant (CFA), a potent
activator of APC, to prevent type 1 diabetes in NOD mice is
well-established, and although protection has been attributed to a
variety of different cells, including suppressor T cells, NK cells and
suppressor macrophages [23–25], the precise mechanism is
unknown. In the present study, we investigated whether CFA
could act at least in part by enhancing the ability of NOD APC to
activate NOD CD4
+CD25
+ regulatory cells that can control
autoreactive T cells and prevent disease in NOD mice.
Methods
Mice
C57BL/6 and NOD female mice from 6 to 34 weeks of age
(Jackson Laboratory, Bar Harbor, ME), and 8-week-old female
OVE26 and FVB mice (gift from Dr. Paul Epstein, University of
Louisville, KY) were maintained under specific pathogen-free
conditions as described in the Institutional Animal Care and Use
Committee guidelines.
Antibodies and flow cytometry
APC-anti-CD25, PerCP-anti-CD4, PE-anti-CD103 antibodies
were purchased (BD Pharmingen, San Diego, CA). One million
cells were incubated with Fc block and labeled with antibodies for
20 min in DPBS 1% FCS, 0.1% NaN03, and washed twice. For
membrane-bound TGFb, cells were labeled with biotinylated anti-
TGFb antibody (R&D, Minneapolis, MN) in buffer containing
BSA followed by streptavidin-PE (BD, San Diego, CA). For Foxp3
and granzyme B, cells pooled from multiple culture wells were
intracellularly labeled with either PE-anti-Foxp3 or anti-granzyme
B antibodies (eBioscience, San Diego, CA) according to the
manufacturer’s instructions. Cells were analyzed by FACSH using
a FACScalibur (Becton Dickinson, Palo Alto, CA).
Cell isolation and purification
Pancreatic cells were obtained by successive digestion at 37uCi n
1 mg/ml, 0.5 mg/ml, and 0.25 mg/ml collagenase D for 15 min,
10 min and 6 min, respectively. CD4 cells from lymphoid organs
were enriched using CD4 cell-enrichment columns (R&D,
Minneapolis, MN), then CD25
+ (purity consistently .90%) and
CD25
2 cells purified using PE-anti-CD25 antibody and anti-PE
magnetic beads (Miltenyi Biotech, Auburn, CA) as per the
manufacturer’s instructions. For some experiments, CD4
+CD25
+
regulatory cells were sorted (MoFloH, DakoCytomation, Fort
Collins, CO) to .95% purity.
T cell-depletion of spleen cells
Spleen cells were incubated in lysis buffer (RPMI 1640 with
25 mM Hepes and 0.3% BSA) containing anti-mouse CD90
antibody (Cedarlane, Hornby, Ontario, Canada), then with Low-
Tox-M rabbit complement (1:10; Cedarlane, Hornby, Ontario,
Canada). The purity of the CD3
2 cells was consistently .95%.
Cell culture
For the T cell suppression assay, CD4
+CD25
2 T responder cells
(2.5610
4/well in 96-well round-bottom plates) were cultured in
complete media (RPMI 1640, 10% heat-inactivated FCS, 2 mM
glutamine, 10 mM HEPES, 100 U/ml penicillin G sodium,
100 mg/ml streptomycin sulfate, and 1610
25 M 2-mercaptoeth-
anol) with irradiated spleen cells (APC; 2610
5/well), anti-CD3
antibody (0.5 mg/ml), and with or without CD4
+CD25
+ regula-
tory T cells (2.5610
4/well) for 4 days at 37uCi n5 %C O 2. Cells
were pulsed with [
3H] thymidine (0.5 mCi) for the last 18 hrs.
Percent inhibition was calculated as [(12(responder2regulatory
cell cpm/responder cell cpm))6100]. To evaluate Foxp3 mainte-
nance or granzyme B induction in vitro, CD4
+CD25
+ regulatory T
cells from multiple mice were pooled and sorted, and cultured in
multiple wells (2–4610
4 cells/well) in complete media for 18 or
40 hrs with irradiated T cell-depleted spleen cells (APC; 1610
5)
and anti-CD3 antibody (0.5 mg/ml).
Treatment of mice with CFA
Complete Freund’s adjuvant (CFA) was prepared using non-
viable desiccated Mycobacterium tuberculosis (H37 RA, Difco
Laboratories, Detroit, MI) at 3, 1 or 0.5 mg/ml in PBS and
emulsified in incomplete Freund’s Adjuvant (IFA; Sigma-Aldrich,
St Louis, MO). NOD mice were injected subcutaneously at 6–
8 weeks of age with 100 ml of CFA.
Adoptive transfer assay and assessment of diabetes
Pancreatic LN CD4
+ cells were sorted and transferred (0.4610
6)
by i.v. injection into 4 wk-old female NOD mice. In some
experiments, CD4
+ cells were first depleted of CD25
+ cells by
incubation with anti-CD25 antibody (7D4) and low-Tox rabbit
complement (Cedarlane, Hornby, Ontario, Canada). Blood
glucose was monitored weekly until 30 weeks of age, and mice
were considered diabetic when glucose levels were .300 mg/dl
for two consecutive weeks.
mRNA extraction and real-time PCR
TotalmRNAwas extracted fromCD4
+CD25
+ and CD4
+CD25
2
T cells sorted from lymphoid organs (purity .98%) and reverse
transcribed using Picopure RNA isolation (Arcturus, Mountain
View, CA) and a Taq Man reverse transcriptase kit (Applied
Biosystems, Foster City, CA). cDNA was amplified in duplicate by
real-time PCR using a SYBR Green PCR kit (Applied Biosystems)
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (59-
GGAGCGAGACCCCACTAACA-39 and 59-ACATACTCAGC-
ACCGGCCTC-39) and Foxp3 (59-CCCACCTACAGGCCCTT-
CTC-39 and 59-GGCATGGGCATCCACAGT-39)p r i m e r s .F o x p 3
mRNAamountswere normalized toGAPDH mRNAamounts,and
fold increase compared to CD4
+CD25
2 T cells is represented.
Statistical analysis
Data were analyzed using either the student’s t test, or ANOVA
and the Turkey-Kramer multiple comparisons test, Fisher’s exact
test or Mann-Whitney test. Each experiment was repeated with
reproducible results 2–4 times. One representative experiment is
shown in each figure.
Results
CD4
+CD25
+ T cells from NOD mice express lower levels of
Foxp3
We have found previously that APC from NOD mice are
unable to activate CD4
+CD25
+ regulatory cells properly in vitro
[16]. We speculated that NOD APC may exhibit a similar defect
in vivo in NOD mice, which may be reflected by lower Foxp3
expression in CD4
+CD25
+ cells. We first examined Foxp3
expression in freshly harvested CD4
+CD25
+ cells from non-sick
6 week-old NOD, Sick (.300 dl/ml blood glucose for two
consecutive weeks) 15–20 week-old NOD and age-matched B6
(control) mice. CD4
+CD25
+ cells from lymphoid organs of B6,
Non-Sick and Sick NOD mice were labeled with anti-CD4 and
anti-CD25 antibodies and either sorted (.95% purity) and Foxp3
mRNA quantified by real-time PCR, or also labeled with anti-
Foxp3 antibody and analyzed by FACSH. Interestingly, Foxp3
Activated APC and NOD Treg
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CD4
+CD25
+ cells from Sick NOD compared to B6 mice
(Fig. 1A–C), although the percentages of CD4
+CD25
+ cells
expressing Foxp3 were identical (Fig. 1D). We next evaluated
the age at which decreases in Foxp3 expression can first be
detected in NOD mice. We found that the level of Foxp3
expression in CD4
+CD25
+ cells from 6 week-old normoglycemic
NOD mice was similar to that of B6 mice, but statistically different
from Sick NOD mice (Fig. 1E). In contrast, CD4
+CD25
+ cells
from 10 week-old pre-diabetic NOD mice (i.e., before elevated
glucose can be detected in either urine or blood) expressed Foxp3
at a level that was not statistically different from that of 15–20
week-old Sick NOD mice. However, Foxp3 levels in CD4
+CD25
+
cells from 10-week-old NOD mice were also not statistically
different from that of either 6 week-old NOD or B6 mice (Fig. 1E),
suggesting that by 10 weeks of age CD4
+CD25
+ cells may be just
beginning to show signs of lower Foxp3 expression. By 11 weeks of
age, Foxp3 expression was significantly decreased in pre-diabetic
NOD mice compared to B6 mice (Fig. 1F). Taken together, these
data indicate that the decrease in Foxp3 expression may begin
several weeks before disease onset, i.e., in our facility at about 10–
12 weeks of age, and suggest that high levels of glucose may not
affect Foxp3 expression. To directly evaluate the impact that high
glucose has on Foxp3 expression, we next analyzed CD4
+CD25
+
cells from transgenic mice that were rendered chronically
hyperglycemic beginning shortly after birth by rat insulin
promoter driven expression of calmodulin (OVE26) [26] and
subsequent b cell damage. CD4
+CD25
+ cells from eight week-old
normoglycemic wild-type (FBV strain) and hyperglycemic OVE26
transgenic mice were analyzed for Foxp3 expression, and were
found to express comparable Foxp3 levels (Fig. 1G). We concluded
from these results that Foxp3 expression by CD4
+CD25
+
regulatory T cells is lower in diabetes-prone (NOD) than
diabetes-resistant (B6) mice, and the lower expression of Foxp3
by NOD CD4
+CD25
+ cells is unlikely to be due to exposure to
high glucose levels, although we cannot rule out a possible role for
other metabolites in NOD mice.
NOD APC are less effective than B6 APC in maintaining
Foxp3 expression in CD4
+CD25
+ T cells in vitro
To begin to evaluate the possibility that the lower Foxp3
expression in fresh NOD CD4
+CD25
+ T cells (Fig. 1) may be due
to decreased ability of NOD APC to maintain Foxp3 expression in
vivo, we developed an assay to evaluate the ability of NOD APC to
maintain Foxp3 expression in vitro. CD4
+CD25
+ cells from B6
mice were cultured overnight in the presence of T cell-depleted
irradiated splenic cells (APC) pooled from B6 mice, and anti-CD3
antibody. The following day, the wells containing CD4
+CD25
+ T
cells were pooled and Foxp3 expression was evaluated. As shown
in Table 1, CD4
+CD25
+ T cells stimulated with APC and anti-
CD3 expressed higher levels of Foxp3 (MFI) than unstimulated
cells, suggesting that in the absence of APC-mediated activation
optimal Foxp3 expression by CD4
+CD25
+ T cells is not
maintained. Further, these data indicate that this assay can be
used to evaluate APC efficacy in maintaining Foxp3 expression. In
the next experiment, irradiated T cell-depleted spleen cells (APC)
were pooled from Sick NOD or age-matched B6 mice, and used in
cultures with NOD or B6 CD4
+CD25
+ T cells and anti-CD3
antibody. After overnight culture, cells were collected and
CD4
+CD25
+ T cells evaluated for Foxp3 expression. Although
there were no differences in the percentages of CD4
+CD25
+ cells
expressing Foxp3 (Table 2, third column), the level of Foxp3 (MFI;
Table 2, fourth column) expressed by either B6 or NOD
Figure 1. Foxp3 expression is decreased in CD4
+CD25
+ cells from NOD mice. Cells from lymphoid organs were harvested from 6-week-old
NOD, or 15–20 week-old B6 and Sick NOD mice and pooled. CD4
+CD25
2 and CD4
+CD25
+ cells were sorted (.95% purity), and mRNA was isolated
and real-time PCR performed using Foxp3 and GAPDH primers (A). Cells from lymphoid organs were harvested from 15–20 week-old B6 and Sick NOD
mice (B–D); or 6 and 10-week-old NOD and B6 mice or 15–20 week-old Sick NOD mice (E); or 11 week-old B6 and NOD mice (F); or 8 week-old FVB
wild-type (control) and OVE26 transgenic mice (G). Samples from individual mice were labeled with anti-CD4, CD25 and Foxp3 antibodies, and
CD4
+CD25
+ cells were gated and analyzed for Foxp3 expression (% and MFI) by FACSH (B–G). Each point represents an individual animal. Blood
glucose levels were evaluated weekly beginning at 12 weeks of age, and mice were considered diabetic (Sick) when glucose levels reached 300 dl/ml
and were maintained for at least two consecutive weeks. An * indicates a significant difference from B6 controls at p,0.05.
doi:10.1371/journal.pone.0003739.g001
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+CD25
+ cells stimulated with NOD APC (Table 2, third &
fifth rows, respectively) was decreased compared to B6 or NOD
CD4
+CD25
+ cells stimulated with B6 APC (Table 2, second &
fourth rows, respectively). The magnitude of differences in Foxp3
expression between NOD CD4
+CD25
+ cells stimulated with
NOD and B6 APC in vitro was very similar to the differences
between freshly harvested CD4
+CD25
+ cells from NOD and B6
mice (Fig. 1C), suggesting that ineffective or sub-optimal
stimulation by NOD APC may be responsible for the lower
expression of Foxp3 in NOD CD4
+CD25
+ cells in vivo. We also
compared the ability of 11 week-old pre-diabetic NOD APC and
Sick NOD APC to maintain Foxp3 expression in vitro. Interest-
ingly, the level of Foxp3 expressed by NOD CD4
+CD25
+ cells
stimulated with APC from pre-diabetic NOD mice was lower
compared to cells stimulated with APC from B6 mice, but higher
than cells stimulated with APC from Sick NOD mice (Table 3).
These data suggest that APC from pre-diabetic mice may also start
to exhibit a decreased ability to maintain Foxp3 expression in vitro.
Taken together, these data support the possibility that NOD APC
are less effective at maintaining Foxp3 expression by CD4
+CD25
+
T cells in NOD mice.
Prevention of diabetes following in vivo treatment with
CFA involves induction/activation of CD4
+CD25
+
regulatory cells
Many studies have shown that s.c. injection of complete
Freund’s adjuvant (CFA) can delay onset and decrease incidence
of diabetes in NOD mice [23–25]. CFA contains desiccated
Mycobacterium tuberculosis (MT), a potent activator of APC. We
hypothesized that CFA prevents diabetes in NOD mice by
activating APC that subsequently activate regulatory cells. In
initial experiments, different doses of CFA were evaluated for
efficacy in preventing disease. As shown in Figure 2A, a single s.c.
injection (100 ml) of CFA containing 100 mg of MT at 6 weeks of
age, delayed diabetes onset by about 8 weeks or more, and 60% of
the mice remained disease-free through at least 30 weeks of age.
Injection of a lower (50 mg) or higher dose (300 mg) of MT was less
protective, and therefore, the 100 mg dose of MT was used for all
of the following experiments. These data may indicate that MT
can influence the balance between pathogenic cell and regulatory
cell activation, i.e., a higher dose of MT may tilt the balance in
favor of the pre-existing pathogenic cells, whereas an intermediate
dose may favor regulatory cells. In support of this hypothesis, we
have found that the ratio of anti-inflammatory versus pro-
inflammatory cytokines produced by APC is highly dependent
on the dose and type of stimuli, and can in turn influence disease
development, i.e., prevention versus exacerbation of diabetes,
respectively ([27] and unpublished data).
We next examined the mechanism of CFA-mediated protection
in NOD mice. Because 40% of CFA-treated NOD mice will
eventually develop diabetes and all mice that are going to develop
diabetes will do so by 30 weeks of age, we analyzed Sick and non-
Sick NOD mice that were .30 weeks of age. Lymphocytic
infiltrates in the pancreas of 34-week-old Non-Sick (NS) CFA-
treated and Sick NOD mice were evaluated for Foxp3-expressing
cells by FACS. The pancreas of Non-Sick CFA-treated mice
contained significantly higher percentages of CD4
+Foxp3
+ and
CD4
+CD25
+ cells than Sick NOD mice (Fig. 2B & C), suggesting
that CD4
+CD25
+Foxp3
+ regulatory cells could play a role in
CFA-mediated prevention of disease. To investigate this possibil-
ity, pancreatic LN from Non-Sick (NS) CFA-treated and Sick
NOD mice were collected, and 0.4610
6 purified CD4
+ cells
transferred into 4 week-old female NOD mice. Ninety percent of
the CD4
+CD25
+ T cells from pancreatic LN (pLN) of CFA-
treated NOD mice expressed Foxp3 (Figure 2D), suggesting that
the great majority of the CD4
+CD25
+ cells that were transferred
in the CD4
+ population exhibited a regulatory cell phenotype.
Blood glucose was monitored every week and diabetes incidence
determined through 30 weeks of age. As shown in Figure 2E,
CD4
+ pancreatic LN cells from Non-Sick CFA-treated mice (NS)
significantly delayed disease onset by 8 weeks (i.e., from 12 to
20 weeks) and significantly decreased the incidence of disease by
comparison to untreated control mice (none). CD4
+ pancreatic LN
cells from Sick mice, on the other hand, actually accelerated
Table 2. APC from NOD mice are less efficient at maintaining
Foxp3 expression in vitro.
APC CD4
+CD25
+ cells % Foxp3
+ Foxp3 MFI
B6 B6 90 314
NOD B6 92 249
B6 NOD 92 302
NOD NOD 88 214
CD4
+CD25
+ T cells from 12–15 week-old B6 or Sick NOD mice were cultured
overnight in multiple wells, either alone or with B6 or Sick NOD irradiated T-cell
depleted spleen cells (APC) and anti-CD3 antibody. Cells were pooled and
labeled with anti-CD4, anti-CD25 and anti-Foxp3 antibodies. CD4
+CD25
+ T cells
and APC were pooled from 3 mice. Cells were analyzed for Foxp3 expression by
FACSH after gating on CD4
+CD25
+ cells. Representative results from one of four
experiments are shown.
doi:10.1371/journal.pone.0003739.t002
Table 1. In vitro assay to evaluate APC-mediated
maintenance of Foxp3 expression by CD4
+CD25
+ T cells.
APC CD4
+CD25
+ cells % Foxp3
+ Foxp3 MFI
none B6 95 199
B6 B6 92 284
CD4
+CD25
+ T cells from 12–15 week-old B6 mice were cultured overnight in
multiple wells, either alone or with B6 irradiated T-cell depleted spleen cells
(APC) and anti-CD3 antibody. Cells were pooled and labeled with anti-CD4,
CD25 and anti-Foxp3 antibodies. CD4
+CD25
+ T cells and APC were pooled from
3 mice. Cells were analyzed for Foxp3 expression by FACSH after gating on
CD4
+CD25
+ cells. Representative results from one of two experiments are
shown.
doi:10.1371/journal.pone.0003739.t001
Table 3. APC from pre-diabetic and Sick NOD mice are less
efficient at maintaining Foxp3 expression in vitro.
APC CD4
+CD25
+ cells % Foxp3
+ Foxp3 MFI
B6 NOD 94 232
Pre-diabetic NOD NOD 98 182
Sick NOD NOD 94 147
CD4
+CD25
+ T cells from 12–15 week-old Sick NOD mice were cultured
overnight in multiple wells, either alone or with irradiated T-cell depleted
spleen cells (APC) from B6, pre-diabetic (11 week-old) NOD or Sick NOD mice
and anti-CD3 antibody. Cells were pooled and labeled with anti-CD4, anti-CD25
and anti-Foxp3 antibodies. CD4
+CD25
+ T cells and APC were pooled from 3
mice. Cells were analyzed for Foxp3 expression by FACSH after gating on
CD4
+CD25
+ cells. Representative results from one of two experiments are
shown.
doi:10.1371/journal.pone.0003739.t003
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untreated control mice to 100%. To determine whether
CD4
+CD25
+ regulatory T cells contributed to the transferred
protection, CD4
+ pancreatic LN cells from Non-Sick CFA-treated
mice were depleted of CD25
+ cells (NS CD4
+CD25
2) and
transferred into 4-week-old NOD recipients. Unlike unfractionat-
ed CD4
+ pancreatic LN cells from Non-Sick CFA-treated NOD
mice, CD25
+-depleted CD4
+ cells from the same population were
unable to protect against diabetes and, in fact, transfer of these
cells increased the incidence of disease (to 100%) by comparison to
untreated controls (Fig. 2E). These data suggest that CD4
+CD25
+
regulatory T cells play a significant role in disease prevention
mediated by CFA, and CFA induces/activates CD4
+CD25
+
regulatory T cells that localize to the pancreatic LN and pancreas
of NOD mice.
The ability of NOD APC to activate CD4
+CD25
+ regulatory
T cell function in vitro is enhanced by treatment with CFA
Since CFA appears to enhance CD4
+CD25
+ regulatory T cell
function in vivo (Fig 2) and NOD APC are less effective stimulators
of regulatory cells [16], at least in vitro, there is a possibility that
CFA could be acting by activating NOD APC. Because a number
of CFA-treated NOD mice will eventually develop diabetes and
the mice that are going to develop diabetes will do so by 30 weeks
of age, we analyzed Sick and Non-Sick NOD mice that were
.30 weeks of age. We compared the ability of APC (irradiated
spleen cells) from individual 30 week-old Non-Sick (NS) CFA-
treated or Sick NOD mice, or B6 mice to activate B6 CD4
+CD25
+
regulatory cell function in vitro. To test NOD APC activity without
the added complication of potentially defective NOD CD4
+CD25
+
cells and/or NOD CD4
+CD25
2 responder cells, we initially
compared the ability of NOD APC from untreated Sick and CFA-
treated Non-Sick NOD mice to induce B6 CD4
+CD25
+ regulatory
cell activity in vitro. As shown in Figures 3A & B, CD4
+CD25
+ cells
cultured in the presence of APC from Non-Sick CFA-treated mice
(CFA NS NOD; Fig. 3A, black columns & 3B) suppressed
proliferation of B6 CD4
+CD25
2 responder T cells in a manner
similar to B6 APC (Fig. 3A, white columns & 3B), and to a
significantly greater extent than APC from Sick NOD mice (Fig. 3A,
gray columns & 3B). Interestingly, although APC from Non-Sick
CFA-treated NOD mice activated regulatory cells more effectively
than APC from untreated NOD mice, there were no differences in
their ability to stimulate responder T cells, i.e., NOD APC are less
effective at stimulating responders cells than B6 APC regardless of
their treatment (Fig. 3A). Once we established that APC from Non-
Sick CFA-treated NOD, but not untreated Sick NOD mice, could
activate ‘‘normal’’ B6 CD4
+CD25
+ regulatory cells in vitro,w e
compared their ability to activate NOD CD4
+CD25
+ regulatory
cells. As shown in Figures 3C & D, although not quite as effective as
B6 APC, CFA-treated NOD APC (CFA NOD) were significantly
better than PBS-treated NOD APC in inducing NOD CD4
+CD25
+
regulatory cell function in vitro, i.e., inhibition of proliferation was
Figure 2. Disease-free CFA-treated NOD mice possess potent regulatory cells. Three different doses of CFA containing 50, 100 or 300 mgo f
Mycobacterium tuberculosis or PBS were administered s.c. to 6 week-old NOD mice. An * indicates a significant difference from the PBS control at
p,0.03 (A). Pancreata were harvested from 34 week-old Sick (Sick) or CFA-treated Non-Sick (NS) NOD mice and digested with collagenase. Cells from
individual mice were labeled with anti-CD4, CD25 antibodies, and Foxp3 antibodies and analyzed by FACSH. Each point represents an individual
animal. An ** indicates a significant difference from the Sick NOD group at p,0.05 (B & C). Pancreatic LN cells were harvested from 30-week-old CFA-
treated Non-Sick NOD mice, and labeled with anti-CD4, CD25 and Foxp3 antibodies, and analyzed by FACSH (D). Pancreatic LN cells from 30-week-old
Sick or CFA-treated Non-Sick (NS) were pooled, CD4
+ cells purified and 0.4610
6 cells transferred into 4-wk-old NOD mice. Or purified CD4
+ cells from
pancreatic LN from 30-week-old CFA-treated Non-Sick (NS) were depleted of CD25
+ cells (NS CD4
+CD25
2) and 0.4610
6 of these CD4
+CD25
2 cells
injected into 4-wk-old NOD mice. Blood glucose was monitored weekly and diabetes incidence determined. An *** indicates a significant difference
from the untreated controls at p,0.005 (E).
doi:10.1371/journal.pone.0003739.g002
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versus PBS-treated NOD APC. Altogether, these data indicate that
treatment with CFA enhances the ability of APC from NOD miceto
activate CD4
+CD25
+ regulatory T cells.
APC from CFA-treated NOD mice induce a fully activated
CD4
+CD25
+ regulatory T cell phenotype
Since APC from NOD mice treated with CFA can activate
NOD CD4
+CD25
+ regulatory T cells effectively, we wondered
whether CFA treatment also restored the ability of NOD APC to
induce/maintain expression of markers important for regulatory
cell function that we had found to be downregulated in NOD mice
(Fig. 1). We first examined the expression of Foxp3 since we had
found that NOD APC were defective at maintaining its expression
in CD4
+CD25
+ cells in vitro (Table 2). CD4
+CD25
+ cells purified
from the lymphoid organs of uninjected NOD mice were cultured
overnight in the presence of T cell-depleted irradiated splenic cells
from age-matched B6, Sick NOD or CFA-treated NOD mice and
anti-CD3 antibody. Cells were harvested and Foxp3 expression by
CD4
+CD25
+ cells evaluated. APC from CFA-treated NOD mice
(pink line) increased Foxp3 expression to levels found with B6 APC
(purple line), suggesting CFA enhanced the ability of NOD APC to
maintain Foxp3 expression by CD4
+CD25
+ cells in vitro (Fig. 4A).
We next examined whether CFA increased expression of Foxp3 in
vivo. Spleen, pancreatic LN and pancreas were harvested from age-
matched B6, PBS-treated NOD, and CFA-treated NOD mice
3 weeks after PBS or CFA injection, and Foxp3 expression by
CD4
+CD25
+ T cells evaluated. CFA treatment of NOD mice
produced a significant enhancement in Foxp3 expression by
splenic and pancreatic LN (pLN) CD4
+CD25
+ cells compared to
cells from untreated NOD mice (Fig. 4B & C). Similar results were
found for cells harvested from the pancreas of CFA-treated NOD
mice (Fig. 4D). These data suggest that CFA may mediate its
protective effect by inducing or maintaining optimal levels of
Foxp3 expression by CD4
+CD25
+ regulatory T cells in the
periphery and at the inflammation sites via the activation of APC.
We also evaluated expression of other molecules associated with
regulatory function that are decreased in either freshly harvested
NOD CD4
+CD25
+ cells, i.e., CD103 [28,29] and membrane-
bound TGFb [30], or after culture, i.e., granzyme B. While the
percentages of CD4
+CD25
+ cells expressing CD103 were reduced
in the spleen of NOD mice compared to those from B6 mice, they
were significantly increased in the spleen of NOD mice treated
with CFA compared to those from untreated NOD mice (Fig. 5A).
Although not statistically significant, the percentages of
CD4
+CD25
+ cells expressing mTGFb tended to be higher
(8.5+/21.6% versus 5.9+/21.3%) after CFA treatment. Finally,
we examined the ability of APC from CFA-treated NOD mice to
induce granzyme B (GZB) in CD4
+CD25
+ cells in vitro. GZB is a
Figure 3. APC from CFA-treated NOD mice effectively induce regulatory cell function in vitro. CD4
+CD25
2 responder cells from B6 mice
were cultured with irradiated spleen cells (APC) from individual 30 week-old B6, Non-Sick (NS) CFA-treated or Sick NOD mice, anti-CD3 and either with
or without CD4
+CD25
+ cells from B6 mice (1:1 regulatory:responder ratio; A & B). CD4
+CD25
2 responder cells from NOD mice were cultured with
irradiated spleen cells (APC) from individual 11 week-old NOD mice injected with PBS or CFA three weeks earlier or B6 mice, anti-CD3 and either with
or without CD4
+CD25
+ cells from NOD mice (1:1 regulatory:responder ratio; C & D). Raw cpm data are shown for one representative animal (A & C),
and percent inhibition is shown where each point represents an individual animal (B & D). * and ** indicate significant differences from the respective
proliferation controls (i.e., responders alone; A & C), or B6 APC (B) at p,0.001 and p,0.05, respectively.
doi:10.1371/journal.pone.0003739.g003
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+CD25
+ regulatory T cells may mediate
suppression in vitro [31]. CD4
+CD25
+ cells were pooled from
multiple NOD mice, and cultured for 40 hrs in the presence of T
cell-depleted irradiated splenic cells (APC) pooled from either B6,
PBS-treated or CFA-treated NOD mice and anti-CD3. Cells were
harvested and examined for intracellular GZB. The percentage of
CD4
+CD25
+ cells expressing GZB was reduced when NOD APC
(Fig. 5B, center panel) were used as stimulators by comparison to
B6 APC (Fig. 5B, left panel). Interestingly, CFA increased the
ability of NOD APC to induce GZB production by CD4
+CD25
+
cells (Fig. 5B, right panel). Altogether, the optimal expression of
Foxp3, CD103 and granzyme B in CD4
+CD25
+ cells harvested
from CFA-treated NOD mice or after culture with APC from
CFA-treated NOD mice most likely reflects a fully activated
regulatory cell phenotype, and further supports our hypothesis that
CFA enhances the ability of NOD APC to activate CD4
+CD25
+
regulatory T cells.
Discussion
NOD mice have major defects in immunoregulation [17,32] and
APC function [4–7] that could be involved in the development of
diabetes. Our previous study suggested that defects in NOD APC
could be directly responsible for the lower functional activity of
CD4
+CD25
+ regulatory T cells in NOD mice [16]. In the current
study, we show that activation of APC in vivo by treatment with CFA
appears to significantly enhance the NOD APC’s ability to activate
CD4
+CD25
+ regulatory T cells, as indicated by increased regulatory
activity both in vivo and in vitro. The enhanced regulatory activity
associated with CFA treatment strongly correlated with restoration
of an optimal regulatory cell phenotype, as reflected by increased
Foxp3 expressionandpercentagesofCD4
+CD25
+Tc e l l se x p r e s s i n g
CD103 and granzyme B, and most importantly, by the ability of this
regulatory cell population to keep diabetogenic cells under control.
Although CFA could have a direct effect on the regulatory cells
themselves, our data suggest that its effect is at least in part mediated
through enhancement of the ability of NOD APC to act on NOD
CD4
+CD25
+regulatoryTcellsattworelatedlevels,i.e.,maintaining
them in a state of ‘‘readiness’’ by sustaining Foxp3 expression and
producing optimal activation signals to stimulate regulatory activity.
The effect of CFA on diabetes prevention has been attributed to
various cell types, including tolerogenic macrophages [24], suppres-
sorT cells[25],and morerecentlyNKcells[23].Ourstudysuggests,
for the first time, that CD4
+CD25
+ regulatory T cells may play an
important role in the control of diabetogenic cells and prevention of
diabetes development in CFA-treated disease-free NOD mice.
When CD4
+ cells harvested from the pancreatic LN of disease-free
CFA-treated NOD mice were depleted of CD25
+ cells, the CD4
+
cells lost their ability to prevent diabetes development after transfer
into young NOD mice. Although, we have not ruled out the
possibility that the CD25
+ cells that appear to mediate protection
from diabetes in our model could also include other types of
regulatory cells, e.g., Th2 cells, the fact that 90% of the CD25
+ cells
in the pLN of CFA-treated NOD mice expressed Foxp3 tends to
favor a traditional CD4
+CD25
+ regulatory rather than Th2
phenotype. More importantly, the enhanced ability of APC to
activate CD4
+CD25
+ regulatory cells in vitro may reflect the
mechanism by which CFA mediates regulatory cell activation in
vivo. APC from NOD mice injected with CFA indeed exhibit an
increased aptitude to stimulate CD4
+CD25
+ regulatory cells in vitro,
as indicated by restored regulatory function, sustained Foxp3
expression and induction of granzyme B in CD4
+CD25
+ regulatory
cells. Since there is increasing evidence of crosstalk between DC and
NKcells [33], there isa possibility that CFA-activated APCmay also
Figure 4. CFA treatment enhances Foxp3 expression by CD4
+CD25
+ regulatory T cells in vivo. CD4
+CD25
+ regulatory T cells were cultured
for 24 hrs with APC (irradiated T cell-depleted spleen cells) pooled from 11 week-old B6 or NOD mice injected with PBS or CFA three weeks earlier
and anti-CD3 antibody (A). Spleen (B), pancreatic LN (pLN) (C) and pancreas (D) were harvested from 11 week-old B6 or NOD mice injected with PBS
or CFA three weeks earlier. Cells were labeled with anti-CD4, CD25 and Foxp3 antibodies and analyzed by FACSH gating on CD4
+CD25
+ cells (A–D).
Each point represents an individual animal (B–D). An * indicates a significant difference from PBS-treated NOD (p,0.05).
doi:10.1371/journal.pone.0003739.g004
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diabetes prevention [23].
It is not clear how CFA affects the ability of APC to activate
regulatory cells. The enhancement of regulatory cell-inducing APC
function in NOD mice treated with CFA is likely to be associated with
an increase in expression/production of molecules important for the
development and/or maintenance of CD4
+CD25
+ regulatory cells.
There are many molecules associated with CD4
+CD25
+ regulatory
celldevelopment; CD28/B7costimulation[34,35] as wellas IL-2and
TGFb [36,37], are crucial for the development, survival and
maintenance of CD4
+CD25
+ regulatory cells as well as in vitro and
in vivo conversion of CD4
+CD25
2 cells into CD4
+CD25
+ regulatory
cells [37,38]. Indeed, we have found that the percentage of NOD
APC expressing B7-1 (including dendritic cells, macrophages and B
cells), which is lower than that of B6 APC, is restored after CFA
injection (data not shown). This is particularly significant, since B7-1
has been associated with tolerance in NOD mice, whereas B7-2
appears to be critical for induction of pathogenic responses [39].
Foxp3 is a molecule crucial for the development of CD4
+CD25
+
regulatory cells [11,13]. Importantly, decreases in the levels of
expression of Foxp3 appear to affect the ability of regulatory cells
to control pathogenic cells. T cells with attenuated endogenous
Foxp3 expression exhibit decreased suppressive activity and
expression of regulatory cell signature genes, resulting in the
development of an autoimmune syndrome similar to that of scurfy
mice [15]. In addition, expression of Foxp3 mRNA at the single
cell level has been shown to be impaired in CD4
+CD25
+
regulatory cells from NOD mice [40]. This decline in Foxp3
expression appears to start as early as 8 weeks of age and becomes
more pronounced as the mice become sick, suggesting its
association with the development of type 1 diabetes [40]. Our
data confirm that the expression of Foxp3 at the protein level is
decreased in NOD CD4
+CD25
+ cells, and that this decrease is not
likely to be due to exposure to high glucose levels. Moreover, our
data indicate that CFA-mediated protection strongly correlates
with upregulation of Foxp3 expression by peripheral and
pancreatic CD4
+CD25
+ regulatory cells, and increased infiltration
of CD4
+Foxp3
+ cells into the pancreas. This is similar to a study
showing that treatment with vasoactive intestinal peptide (VIP)
upregulates Foxp3 in the pancreas, and restores tolerance by
promoting the local differentiation and function of regulatory T
cells [41]. We have also found that CFA administration enhances
the percentages of CD4
+CD25
+ regulatory T cells expressing
CD103, thought to be an activated effector/memory-like regula-
tory cell population [29] that exerts potent Ag-nonspecific
suppression in the absence of TCR stimulation [42], and capable
of sustained localization at inflammation sites [28,29]. Culture of
NOD regulatory cells with APC from CFA-treated NOD mice
recapitulates the in vivo effect of CFA, as indicated by the increase
in Foxp3 and granzyme B expression. The upregulation of Foxp3,
CD103 and granzyme B expression may reflect restoration of a
fully activated regulatory cell population, which may be crucial for
the regulation of pathogenic cells and prevention of diabetes
development. Upon stimulation with CFA, NOD APC may gain
the ability to fully activate functional NOD regulatory cells that
can successfully control pathogenic cells.
In conclusion, our study has provided ‘‘proof-of-concept’’ that
manipulating the ability of APC to activate/induce CD4
+CD25
+
regulatory T cells is a potential strategy that can be used to prevent
disease. However, finding the optimal and specific stimulus as well
as identifying molecules that will target only regulatory cells, and
not pathogenic cells, will be crucial for developing therapies to
prevent and treat diabetes in humans. A cell wall molecule of M.
tuberculosis, Mannose-capped lipoarabinomannan (ManLAM), has
been shown to induce expansion of CD4
+CD25
+Foxp3
+ regula-
tory T cells by binding to receptors expressed by APC [43].
ManLAM may, therefore, be a potential candidate for enhancing
the ability of APC to induce preferentially regulatory cells.
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